Price
CHART BY
Frequently asked questions
What is Rezolute's market capitalization?
The market capitalization of Rezolute is $274.23M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Rezolute?
Rezolute's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.221. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Rezolute's stock?
Currently, 8 analysts cover Rezolute's stock, with a consensus target price of $13.25. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Rezolute?
Rezolute's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$73.30M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Rezolute?
Rezolute has a free cash flow of -$63.44M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Rezolute have, and what sector and industry does it belong to?
Rezolute employs approximately 59 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Rezolute's shares?
The free float of Rezolute is 49.03M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $274.23M
- EPS (TTM)
- -$1.221
- Free Float
- 49.03M
- EBITDA (TTM)
- -$73.30M
- Free Cashflow (TTM)
- -$63.44M
Pricing
- 1D span
- $4.488$4.994
- 52W span
- $1.59$6.18
Analyst Ratings
The price target is $13.25 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug, a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, and RZ402, an oral plasma kallikrein inhibitor and potential therapy for the chronic treatment of diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
- Employees
- 59
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US76200L3096
- Primary Ticker
- RZLT
Knockouts
Finance data from FactSet